Lexicon Pharmaceuticals | LXRX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Abbott USD 1.74B 2.94M 2026-03
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Illumina USD 151.3M 607K 2026-06
Insmed USD 218.28M 1.76M 2026-06
Ironwood Pharmaceuticals USD 160K 0 2024-12
J&J USD 2.41B 1.35M 2026-03
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
MacroGenics USD 63.56M 241K 2026-03
MannKind USD 309.91M 1M 2026-06
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Novartis USD 1.9B 7.38M 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
Thermo Fisher Scientific USD 371.62M 1000 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.68M 521K 2026-06
Vanda Pharmaceuticals USD 58K 0 2024-12